Firms
Theme

BKD

Brookdale Senior Living, Inc. · NYSE

News

3 latest

Zacks Investment Research

Brookdale (BKD) Upgraded to Strong Buy: Here's Why

Brookdale Senior Living (BKD) has been upgraded to Zacks Rank #1 (Strong Buy) following a 160% increase in consensus earnings estimates over the past three months. The upgrade reflects improving business fundamentals and positions the stock in the top 5% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by positive earnings momentum.

Zacks Investment Research

Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?

Acadia Healthcare (ACHC) is significantly outperforming the Medical sector, with year-to-date returns of 97.8% compared to the sector average of 0.2%. The company holds a Zacks Rank #2 (Buy) with improving analyst sentiment, as consensus earnings estimates have increased 3.5% in the past quarter. Brookdale Senior Living (BKD) is also highlighted as another outperforming Medical stock with a 0.7% return and 160% increase in EPS estimates.

Mentions BKD

Zacks Investment Research

Ensign Builds More Scale as Financial Flexibility Remains Strong

The Ensign Group expanded its skilled nursing operations by acquiring 20 facilities across Florida, Washington, and Colorado, entering Florida for the first time. With $262.3M in cash, minimal long-term debt of $135.6M, and $591.6M in available credit, the company is well-positioned for continued growth. The acquisitions bring Ensign's total portfolio to 418 healthcare operations across 18 states.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $BKD · 0 threads

Sign in to post on $BKD

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev